Assembly biosciences doses first participant in phase 1a/b clinical trial of herpes simplex virus helicase-primase inhibitor candidate abi-5366

– phase 1a study portion of single ascending dosing in healthy participants will inform the development of abi-5366 with interim data expected in q3 2024 –

ASMB Ratings Summary

ASMB Quant Ranking